Related Experiment Videos

Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with

Insights

Dapsone-induced hemolytic anemia is not caused by impaired glucose-6-phosphate dehydrogenase (G-6-PD) activity. A toxic dapsone derivative, DDS-NHOH, is likely responsible for methaemoglobin production and anemia.

Area of Science:

  • Pharmacology
  • Hematology
  • Biochemistry

Background:

  • Dapsone is a medication used to treat various dermatoses.
  • Dapsone administration can lead to methaemoglobin production and hemolytic anemia.
  • The role of glucose-6-phosphate dehydrogenase (G-6-PD) in these adverse effects is unclear.

Purpose of the Study:

  • To investigate the hypothesis that dapsone-induced methaemoglobin production and hemolytic anemia are due to impaired G-6-PD enzymatic activity.
  • To analyze the kinetic parameters of G-6-PD in patients receiving dapsone therapy.

Main Methods:

  • Kinetic analysis of G-6-PD (Vmax and KM) was performed.
  • Ten patients with various dermatoses, normal for G-6-PD, were included in the study.

Main Results:

  • The study found no functional impairment of G-6-PD in patients experiencing dapsone-induced adverse effects.
  • A strong correlation was observed between dapsone dosage, methaemoglobin production, and anemia.

Conclusions:

  • Hemolytic anemia following dapsone therapy is not attributed to a functional impairment of G-6-PD.
  • A toxic dapsone derivative, DDS-NHOH, is hypothesized to be responsible for methaemoglobin formation and hemolytic anemia.

Related Concept Videos